Healthcare tech company GoodRx (NASDAQ: GDRX) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales fell by 1.3% year on year to $200.4 million. The company’s full-year revenue guidance of $797.5 million at the midpoint came in 2.8% above analysts’ estimates. Its non-GAAP profit of $0.08 per share was in line with analysts’ consensus estimates.
Is now the time to buy GDRX? Find out in our full research report (it’s free for active Edge members).
GoodRx (GDRX) Q2 CY2026 Highlights:
- Revenue: $200.4 million vs analyst estimates of $193.6 million (1.3% year-on-year decline, 3.5% beat)
- Adjusted EPS: $0.08 vs analyst estimates of $0.08 (in line)
- Adjusted EBITDA: $63.74 million vs analyst estimates of $59.8 million (31.8% margin, 6.6% beat)
- The company lifted its revenue guidance for the full year to $797.5 million at the midpoint from $775 million, a 2.9% increase
- EBITDA guidance for the full year is $245 million at the midpoint, above analyst estimates of $238.3 million
- Operating Margin: 11.8%, down from 13.2% in the same quarter last year
- Market Capitalization: $1.26 billion
StockStory’s Take
GoodRx’s second quarter results drew a positive market response, reflecting outperformance driven by rapid growth in Pharma Direct and expanding subscription adoption. Management attributed the momentum to accelerating manufacturer partnerships, especially in GLP-1 access programs, and successful execution of new offerings like GoodRx Companion. CEO Wendy Barnes highlighted that, “the second quarter was a standout for Pharma Direct, with revenue growing 76% year-over-year, supported by strength in consumer direct pricing and advertising solutions.” The company’s deliberate pivot towards higher-margin, recurring revenue streams was evident, even as legacy prescription transaction metrics moderated.
Looking ahead, GoodRx’s upgraded full-year guidance is anchored by continued scaling of Pharma Direct and accelerating adoption of its expanded subscription platform. Management pointed to the breadth of manufacturer partnerships and the early traction of Companion as key drivers for sustained top-line growth. Barnes noted, “as we deliver against that plan, we are confident it will translate into a more durable growth profile and long-term value.” The company also expects ongoing affordability pressures in the healthcare market to support demand for its suite of consumer-centric offerings, while investments in AI and operational efficiency are intended to bolster profitability and execution.
Key Insights from Management’s Remarks
Management credited the quarter’s results to robust growth in Pharma Direct, strengthening subscription offerings, and increased engagement from both consumers and pharmaceutical partners.
-
Pharma Direct expansion: GoodRx’s Pharma Direct segment saw a 76% year-over-year revenue increase, fueled by growing manufacturer adoption of consumer direct pricing programs, particularly for high-demand GLP-1 therapies. Management emphasized that this growth came from both new and expanded relationships with leading pharmaceutical brands.
-
GLP-1 demand remains strong: The company continued to support major GLP-1 launches, such as oral versions and higher-dose formulations, cementing its role as a leading channel for these therapies. Management stated that GLP-1 demand is robust, especially in the self-pay segment, and expects this momentum to persist as coverage models change.
-
Subscription model gains traction: Subscriptions, including the launch of GoodRx Companion, became a central focus. Subscription plans grew 14% year-over-year, with management highlighting early adoption of Companion, which targets broader consumer healthcare needs and offers expanded pharmacy access and benefits.
-
Retail pharmacy network enhancements: GoodRx invested in its nationwide pharmacy network, expanding direct contracting and enabling e-commerce capabilities at nearly 6,000 locations. The network improvements are designed to increase consumer choice and reduce friction at the pharmacy counter.
-
Leadership transition: The company announced that Justin Fengler, previously Chief Strategy and Operations Officer, has been appointed Chief Financial Officer, bringing experience in strategy, operations, and financial management to the role.
Drivers of Future Performance
GoodRx expects the combination of Pharma Direct scaling and subscription expansion to drive revenue growth and margin durability, while macro healthcare affordability trends and operational investments shape the outlook.
-
Pharma Direct as a growth engine: Management believes continued manufacturer adoption and expansion of direct pricing programs, especially for high-value therapies like GLP-1s, will be a primary revenue driver. The team expects the Pharma Direct segment’s growth to more than offset declines in legacy prescription transaction revenue.
-
Subscription platform scaling: The company is prioritizing the shift toward subscriptions, led by GoodRx Companion and tailored offerings, to build recurring revenue and deepen consumer engagement. Management highlighted that while the transition may moderate traditional transaction metrics, it is designed to deliver higher lifetime value and more predictable revenue.
-
Operational efficiency and AI investments: Investments in AI-powered workflow automation and improved operating leverage are expected to enhance execution and support profitability. However, management acknowledged that shifting product mix and cost to serve subscriptions could create some margin variability in the near term.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) continued growth and retention in the new Companion subscription platform, (2) the pace and breadth of manufacturer adoption in Pharma Direct, and (3) progress on scaling Employer Direct partnerships. Developments in healthcare affordability and regulatory approval for emerging therapies, such as peptides, will also be critical to track.
GoodRx currently trades at $3.68, up from $3.27 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
